Oct 2026
Early Recurrence Limits Post-recurrence Therapy in Biliary Tract Cancer: A Rationale for Neoadjuvant Chemotherapy.
Patients with resectable BTC with elevated CA19-9 or clinical lymph node positivity are at high risk of early recurrence and limited treatment feasibility after recurrence, and NAC may improve outcomes in this population by delaying recurrence.
Daisaku Yamada, H. Akita, Yosuke Mukai et al.
· Annals of Surgical Oncology · 1 citation